534 related articles for article (PubMed ID: 17919118)
1. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
2. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
Richardson D; Ponka P; Baker E
Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
Hoyes KP; Jones HM; Abeysinghe RD; Hider RC; Porter JB
Exp Hematol; 1993 Jan; 21(1):86-92. PubMed ID: 8417963
[TBL] [Abstract][Full Text] [Related]
4. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Evans P; Kayyali R; Hider RC; Eccleston J; Porter JB
Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
[TBL] [Abstract][Full Text] [Related]
6. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
Vlachodimitropoulou Koumoutsea E; Garbowski M; Porter J
Br J Haematol; 2015 Sep; 170(6):874-83. PubMed ID: 26033030
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines.
Hoyes KP; Hider RC; Porter JB
Cancer Res; 1992 Sep; 52(17):4591-9. PubMed ID: 1511427
[TBL] [Abstract][Full Text] [Related]
8. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
Ambrus CM; Stadler I; Toumbis CA; Stadler A; Anthone S; Anthone R; DeAlarcon P; Deshpande G; Conway J; Vladutiu AO; Ambrus JL
J Med; 1999; 30(3-4):211-24. PubMed ID: 17312675
[TBL] [Abstract][Full Text] [Related]
9. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Chaston TB; Richardson DR
Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
[TBL] [Abstract][Full Text] [Related]
10. Chelation of bismuth by combining desferrioxamine and deferiprone in rats.
Tubafard S; Fatemi SJ
Toxicol Ind Health; 2008 May; 24(4):235-40. PubMed ID: 19022876
[TBL] [Abstract][Full Text] [Related]
11. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
Blood; 2001 Feb; 97(3):792-8. PubMed ID: 11157499
[TBL] [Abstract][Full Text] [Related]
12. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
Hoyes KP; Porter JB
Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
[TBL] [Abstract][Full Text] [Related]
13. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.
Maclean KH; Cleveland JL; Porter JB
Blood; 2001 Dec; 98(13):3831-9. PubMed ID: 11739193
[TBL] [Abstract][Full Text] [Related]
14. Effect of desferrioxamine, rhodotorulic acid and cholylhydroxamic acid on transferrin and iron exchange with hepatocytes in culture.
Baker E; Page M; Torrance J; Grady R
Clin Physiol Biochem; 1985; 3(6):277-88. PubMed ID: 4075694
[TBL] [Abstract][Full Text] [Related]
15. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
16. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
17. Removal of thallium by combining desferrioxamine and deferiprone chelators in rats.
Amiri A; Fatemi SJ; Fatemi SN
Biometals; 2007 Apr; 20(2):159-63. PubMed ID: 16927173
[TBL] [Abstract][Full Text] [Related]
18. Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.
Sooriyaarachchi M; Gailer J
Dalton Trans; 2010 Aug; 39(32):7466-73. PubMed ID: 20623073
[TBL] [Abstract][Full Text] [Related]
19. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
20. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Kontoghiorghes GJ; Kolnagou A; Skiada A; Petrikkos G
Hemoglobin; 2010 Jun; 34(3):227-39. PubMed ID: 20524813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
